Investing.com - Biofrontera ADR reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Biofrontera ADR announced earnings per share of $-0.23 on revenue of $6.8M. Analysts polled by Investing.com anticipated EPS of $-0.215 on revenue of $7.26M.
Biofrontera ADR shares are down 20.71% from the beginning of the year, still down 59.86% from its 52 week high of $14.40 set on August 21, 2020. They are under-performing the Nasdaq which is up 12.83% from the start of the year.
Biofrontera ADR follows other major Healthcare sector earnings this month
Biofrontera ADR's report follows an earnings beat by Abbott Labs on July 22, who reported EPS of $1.17 on revenue of $10.22B, compared to forecasts EPS of $1.02 on revenue of $9.69B.
Merck ADR had beat expectations on August 5 with second quarter EPS of $0.5304 on revenue of $5.77B, compared to forecast for EPS of $0.4897 on revenue of $5.63B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar